Biobanking for Rare Diseases – Impact on Personalised Medicine

  • Jeanne-Hélène di DonatoEmail author
Part of the Advances in Predictive, Preventive and Personalised Medicine book series (APPPM, volume 6)


For the past 15 years biobanks have been infrastructures that have permitted to ensure the quality of the biological resources used as well as guarantee the rights of stakeholders. Due to their medical and scientific expertise, they offer collections of human biological resources that meet with research project requirements. Because of their secure storage capacities, biobanks are front-line actors in collection management by enabling their development, ensuring their continued existence and their valorisation in relevant research projects. At the cross-roads of patient inclusion, sample and associated data collection and logistical facilities, biobanks have become a significant partner of translational research and personalised medicine, almost essential in the field of rare diseases research as a result of the difficulty of obtaining the samples.


Biobanks Repositories Collection Bioresources Human samples Rare diseases Ethic Best practice Personalised medicine 


  1. 1.
    Oktay MH, Hui P (2012) Molecular pathology as the driving force for personalized oncology. Expert Rev Mol Diagn 12(8):811–813PubMedCrossRefGoogle Scholar
  2. 2.
    Kalia M (2013) Personalized oncology: recent advances and future challenges. Metabolism 62:S11–S14, Suppl1PubMedCrossRefGoogle Scholar
  3. 3.
    Palau F (2012) Personalized medicine in rare disease. Personalized Med 9(2):137–141CrossRefGoogle Scholar
  4. 4.
    Rugnetta M, Whitney K (2009) Paving the way for personalized medicine. Sci Prog. Accessed 12 Dec 2012
  5. 5.
    Lehrach H (2012) A revolution in healthcare: challenges and opportunities for personalized medicine. Personalized Med 9(2):105–108CrossRefGoogle Scholar
  6. 6.
    Clotworthy M (2012) The application of human tissue for drug discovery and development. Expert Opin Drug Discov 7(7):543–547PubMedCrossRefGoogle Scholar
  7. 7.
    Yüzbaşioğlu A, Ozgüç M (2012) Biobanking: sample acquisition and quality assurance for ‘omics’ research. N Biotechnol 30(3):339–342PubMedGoogle Scholar
  8. 8.
    OECD (2000) Biological resources centres: underpinning the future of life sciences and biotechnology. DSTI/STP/BIO 4 REV1 Accessed 30 Dec 2012
  9. 9.
    European Strategy Forum in Research Infrastructures (ESFRI) (2012) European research infrastructures with global impact. Accessed 30 Dec 2012
  10. 10.
    Meeting Europe’s challenges: the role and importance of biological and medical sciences research infrastructures (2010) Accessed 30 Dec 2012
  11. 11.
    Meijer I, Mattson P, Nooijen A, Boekholt P, Molas Gallart J, Amat CB (2010) BBMRI: an evaluation strategy for socio-economic impact assessment Accessed 30 Dec 2012
  12. 12.
    OECD best practice guidelines for biological resource centres (2007) Accessed 30 Dec 2012
  13. 13.
    Gottweis H, Kaye J, Bignami F, Rial-Sebbag E, Lattanzi R, Macek M (2012) Biobanks for Europe – a challenge for governance. doi: 10.2777/68942. Accessed 30 Dec 2012
  14. 14.
    Martín Uranga A, Martín-Arribas MC, di Donato JH, de la Paz Posada M (2005) Outstanding legal and ethical issues on biobanks. Instituto de Salud Carlos III, MadridGoogle Scholar
  15. 15.
    Norme NF S 96–900: Quality of Biological Resources Centres (BRC) – Quality management system of BRC and quality of biological resources. (2011) French documentGoogle Scholar
  16. 16.
    Martín Uranga A, Martín-Arribas MC, di Donato JH, de la Paz Posada M (2005) Outstanding legal and ethical issues on biobanks. Instituto de Salud Carlos III, Madrid, Chapter 6Google Scholar
  17. 17.
  18. 18.
    OECD best practice guidelines for biological resource centres (2007) Chapter best practice guidelines on human-derived material. Accessed 30 Dec 2012
  19. 19.
    Lochmüller H, Aymé S, Pampinella F, Melegh B, Kuhn K, Antonarakis SE, Meitinger T (2009) The role of biobanking in rare diseases: European Consensus Expert Group report. Biopreserv Biobank 7(3):155–156PubMedCrossRefGoogle Scholar
  20. 20.
    Lochmüller H, Schneiderat P (2010) Biobanking in rare disorders. Adv Exp Med Biol 686:105–113PubMedCrossRefGoogle Scholar
  21. 21.
    RD-CONNECT: an integrated platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research. Accessed 30 Dec 2012
  22. 22.
    International Rare Disease Research Consortium. Accessed 30 Dec 2012
  23. 23.
    Rare disorders research consortium of Oregon Health & science university. Accessed 30 Dec 2012
  24. 24.
    Treat-NMD neuromuscular network. Accessed 30 Dec 2012
  25. 25.
    Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R, Hayes DF, Hainaut P, Kim P, Mansfield EA, Potapova O, Riegman P, Rubinstein Y, Seijo E, Somiari S, Watson P, Weier HU, Zhu C, Vaught J (2011) Biospecimen reporting for improved study quality (BRISQ) Cancer Cytopathology. Cancer Cytopathol 119(2):92–102. doi  10.1002/cncy.20147
  26. 26.
    Azimi-Nezhad M, Lambert D, Ottone C, Perrin C, Chapel C, Gaillard G, Pfister M, Masson C, Tabone E, Betsou F, Meyronet D, Ungeheuer MN, S-Siest V (2012) Influence of pre-analytical Variables on VEGF gene expression and circulating protein concentrations. Biopreserv Bioreposit 10(5):454–461CrossRefGoogle Scholar
  27. 27.
    González-Gross M, Breidenassel C, Gómez-Martínez S, Ferrari M, Béghin L, Spinneker A, Díaz LE, Maiani G, Demailly A, Al-Tahan J, Albers U, Wärnberg J, Stoffel-Wagner B, Jiménez-Pavón D, Libersa C, Pietrzik K, Marcos A, Stehle P (2008) Sampling and processing of fresh blood samples within a European multicenter nutritional study: evaluation of biomarker stability during transport and storage. Int J Obes (Lond) 32(Suppl 5):S66–S75CrossRefGoogle Scholar
  28. 28.
    Lehmann S, Roche S, Allory Y, Barthelaix A, Beaudeux JL, Berger F, Betsou F, Borg J, Dupuy A, Garin J, Quillard M, Lizard G, Peoc’h K, Riviere M, Ducoroy P (2009) Preanalytical guidelines for clinical proteomics investigation of biological fluids. Ann Biol Clin (Paris) 67(6):629–639, FrenchGoogle Scholar
  29. 29.
    Stumm MM, Walker MR, Stork C, Hanoteau N, Wagner U, O’Reilly TM (2012) Validation of a postfixation tissue storage and transport medium to preserve histopathology and molecular pathology analyses (total and phosphoactivated proteins, and FISH). Am J Clin Pathol 137(3):429–436PubMedCrossRefGoogle Scholar
  30. 30.
    Rai AJ, Vitzthum F (2006) Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics. Expert Rev Proteomics 3:409–426PubMedCrossRefGoogle Scholar
  31. 31.
    Policepatil SM, Caplan RH, Dolan M (2012) Hypocalcemic myopathy secondary to hypoparathyroidism. Wisc Med Soc 111(4):173–175Google Scholar
  32. 32.
    Amann G, Zehntner C, Marti F, Colucci G (2012) Effect of acceleration forces during transport through a pneumatic tube system on ROTEM® analysis. Clin Chem Lab Med 50(8):1335–1342PubMedCrossRefGoogle Scholar
  33. 33.
    OECD best practice guidelines for biological resource centres (2007) Chapter II, p 16. Accessed 30 Dec 2012
  34. 34.
    Marko-Vaga G, Végvari A, Welinder C, Lindberg H, Rezeli M, Edula G, Svensson KJ, Belting M, Laurell T, Fehniger T (2012) Standardization and utilization of biobank resources in clinical protein science with examples of emerging applications. J Proteome Res 11(11):5124–5134CrossRefGoogle Scholar
  35. 35.
    Kugler KG, Hackl WO, Mueller L, Fiegl H, Graber A, Pfeiffer R (2011) The impact of sample storage time on estimates of association in biomarker discovery studies. J Clin Bioinform 1:9CrossRefGoogle Scholar
  36. 36.
    P3G Accessed 30 Dec 2012
  37. 37.
    I3-CRB Accessed 30 Dec 2012
  38. 38.
    EuroBioBank Accessed 30 Dec 2012
  39. 39.
    TV GSO: Virtuel tumor bank of Canceropole GSO Accessed 30 Dec 2012
  40. 40.
    Clerkin P, Buckley BS, Murphy AW, MacFarlane AE (2012) Patients’ views about the use of their personal information from general practice medical records in health research: a qualitative study in Ireland. Fam Pract. doi: 10.1093/fampra/cms036 PubMedGoogle Scholar
  41. 41.
    Kosseim P (2011) Banking for the future: “Informing” consent in the context of biobanks. Paper submitted at the OIV International Seminar on the UNSECO Universal Declaration on Bioethics and Human rights. Accessed 30 Dec 2012
  42. 42.
    Ensuring Consent & Revocation – A collaborative IT research project being undertaken by UK industry & academia. Accessed 30 Dec 2012
  43. 43.
    Presidential Commission for the study of bioethical issues (2012) Privacy and progress in whole genome sequencing. Accessed 12 Dec 2012
  44. 44.
    Soto C, Tarrant C, Pritchard-Jones K, Dixon-Woods M (2012) Consent to tissue banking for research: qualitative study and recommendations. Arch Dis Child 97:632–636PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2015

Authors and Affiliations

  1. 1.3C-RCastelginestFrance

Personalised recommendations